Skip to content

Ketamine: all studies

Page 212 of 449: studies 2,111 to 2,120 of 4,486, newest first. Back to the ketamine overview

Research

Ketamine Produces a Long-Lasting Enhancement of CA1 Neuron Excitability

bioRxiv Preprint Server May 26, 2021 Grace N Jang, M Bruce MacIver 1 citation preprint

Background Ketamine is a clinical anaesthetic and a fast-acting, long-lasting antidepressant. Ketamine is known for its antagonistic actions on N-methyl-D-aspartate (NMDA) receptors, but mechanisms leading to antidepression are not clear. The present study examined synaptic, neuronal and circuit-level loci, the duration of ketamine’s actions, and the involvement of NMDA receptors in these actions.

Ketamine in the treatment of cocaine use disorders

Ciência e Natura May 20, 2021 Ronaldo Cascelli Schelb Scalla Pereira, Emanuelle Emília Ferreira Parreiras, Davi Cascelli Schelb Scalla Pereira et al.

Introduction: ketamine is a dissociative anesthetic and, recently, its antidepressant properties has been described. Besides, its safety has been proven in the treatment of Stimulant Use Disorders. Objective: to evaluate the use of ketamine in the treatment of Stimulant Use Disorders (specially cocaine and its byproducts). Methods: patient's motivation for change was measured by URICA scale and...

DOI: 10.5902/2179460x44077 (opens in new tab) Ketamine Intervention counseling Stimulant Antidepressant +4

Ketamine's schizophrenia-like effects are prevented by targeting PTP1B.

Neurobiology of Disease May 17, 2021 Zhaohong Qin, Li Zhang, Michael A. Zasloff et al.

Subanesthetic doses of ketamine induce schizophrenia-like behaviors in mice including hyperlocomotion and deficits in working memory and sensorimotor gating. Here, we examined the effect of in vivo ketamine administration on neuronal properties and endocannabinoid (eCB)-dependent modulation of synaptic transmission onto layer 2/3 pyramidal neurons in brain slices of the prefrontal cortex, a...

Combining Ketamine and Internet-Based Cognitive Behavioral Therapy for the Treatment of Posttraumatic Stress Disorder: Protocol for a Randomized Controlled Trial

JMIR Research Protocols May 11, 2021 A. Philipp-Muller, Taras Reshetukha, Gustavo Vazquez et al.

Background Over one third of patients with posttraumatic stress disorder (PTSD) do not respond to current interventions. Ketamine presents a potential treatment option; however, its effects are temporary. Administering ketamine alongside psychotherapy is one potential means of prolonging its effects; however, only a few studies have investigated this treatment method to date, and none have...

Repeated Dosing of Ketamine in the Forced Swim Test: Are Multiple Shots Better Than One?

Frontiers in Psychiatry May 11, 2021 Ridge G. Weston, Paul J. Fitzgerald, Brendon O. Watson 19 citations

The anesthetic drug ketamine has been successfully repurposed as an antidepressant in human subjects. This represents a breakthrough for clinical psychopharmacology, because unlike monoaminergic antidepressants, ketamine has rapid onset, including in Major Depressive Disorder (MDD) that is resistant to conventional pharmacotherapy. This rapid therapeutic onset suggests a unique mechanism of...

The Safety, Clinical, and Neurophysiological Effects of Intranasal Ketamine in Patients Who Do Not Respond to Electroconvulsive Therapy: Protocol for a Pilot, Open-Label Clinical Trial

JMIR Research Protocols May 10, 2021 Yuliya Knyahnytska, Daniel M. Blumberger, Tyler S Kaster et al.

Background Major depressive disorder is among the most disabling illnesses worldwide, with a lifetime prevalence of 16.2%. Research suggests that 20% to 40% of patients with depression do not respond to pharmacotherapy, developing treatment-resistant depression. Electroconvulsive therapy is the gold standard for treating individuals with treatment-resistant depression, with remission rates of...

The anterior cingulate cortex as a key locus of ketamine’s antidepressant action

Neuroscience & Biobehavioral Reviews May 10, 2021 Laith Alexander, Luke A. Jelen, Mitul A. Mehta et al. 79 citations

The subdivisions of the anterior cingulate cortex (ACC) - including subgenual, perigenual and dorsal zones - are implicated in the etiology, pathogenesis and treatment of major depression. We review an emerging body of evidence which suggests that changes in ACC activity are critically important in mediating the antidepressant effects of ketamine, the prototypical member of an emerging class of...

DOI: 10.1016/j.neubiorev.2021.05.003 (opens in new tab) Ketamine Antidepressant Anterior cingulate cortex Cognition +2

Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial.

Journal of Psychiatric Research May 8, 2021 Rodrigo P Mello, Mariana V F Echegaray, A. P. Jesus-Nunes et al. 22 citations

Dissociative symptoms are common, possibly severe, side effects associated with the use of ketamine and esketamine in depression. We investigated the relationship between trait dissociation and dissociation induced by ketamine and esketamine used as augmentation therapy in treatment-resistant depression (TRD). Adults with TRD were randomly assigned to receive a single intravenous infusion, with...

Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor

Molecular Psychiatry May 7, 2021 Wei Yan, Lijia Chang, Kenji Hashimoto 242 citations

The discovery of robust antidepressant actions exerted by the N-methyl-D-aspartate receptor (NMDAR) antagonist (R,S)-ketamine has been a crucial breakthrough in mood disorder research. (R,S)-ketamine is a racemic mixture of equal amounts of (R)-ketamine (arketamine) and (S)-ketamine (esketamine). In 2019, an esketamine nasal spray from Johnson & Johnson was approved in the United States of...

Magnesium in Ketamine Administration in Treatment-Resistant Depression

Pharmaceuticals May 3, 2021 Natalia Górska, Wiesław Jerzy Cubała, Jakub Słupski et al. 2 citations

Relationship between depression and magnesium levels is reported. This observational study examined whether serum magnesium concentration change over time of ketamine treatment course, also whether association between magnesium concentrations and treatment response measured with Montgomery-Åsberg Depression Rating Scale (MADRS) score occurs. Moreover, interlink between changes in Young Mania...

DOI: 10.3390/ph14050430 (opens in new tab) Ketamine Magnesium Depression economics Mania +7